Abstract
Background This study aimed to examine whether there have been sustained impacts of the Covid-19 pandemic on smoking patterns in England.
Methods Data were from 101,960 adults (≥18y) participating in a monthly representative household survey between June-2017 and August-2022. Interview were conducted face-to-face until March 2020 and via telephone thereafter. Generalised additive models estimated associations of the pandemic onset (March-2020) with current smoking, uptake, cessation, quit attempts, medium-term abstinence, and use of support. Models adjusted for seasonality, sociodemographic characteristics, and (where relevant) dependence and tobacco control mass-media expenditure.
Findings Before the Covid-19 pandemic, smoking prevalence fell by 5.2% per year; this rate of decline slowed to 0.3% per year during the pandemic (RRΔtrend=1.06, 95%CI=1.02-1.09). This slowing was evident in more but not less advantaged social grades (RRΔtrend=1.15, 1.08-1.21; RRΔtrend=1.00, 0.96-1.05). There were sustained step-level changes in different age groups: a 34.9% (95%CI=17.7-54.7%) increase in smoking prevalence among 18-24-year-olds, indicating a potential rise in uptake, in contrast to a 13.6% (95%CI=4.4-21.9%) decrease among 45-65-year-olds. There were sustained increases in quitting among past-year smokers, with a 120.4% (95%CI=79.4-170.9%) step-level increase in cessation and a 41.7% (95%CI=29.7-54.7%) increase in quit attempts.
Interpretation In England, the rate of decline in adult smoking prevalence stagnated during the Covid-19 pandemic. Potential reductions in smoking prevalence among middle-aged adults and sustained increases in quitting among smokers may have been offset by a sustained rise in uptake among young adults. The slowing in the rate of decline was pronounced in more advantaged social grades.
Funding Cancer Research UK.
Evidence before this study We searched PubMed up to 1 September 2022 for papers on the Covid-19 pandemic and changes in smoking patterns among adults in England published since March 2020, using the terms “smok*” AND (“Covid*” OR “pandemic”) AND (“England” OR “UK”) AND “adults”. Of the 167 studies that were identified, none reported on trends in smoking behaviour among adults in England during the Covid-19 pandemic using more than two data points. Three prospective studies compared smoking and quitting behaviour before and during the initial stages of the pandemic using a pre-post design: two observed no notable change in smoking prevalence but documented increases in quit attempts and cessation during the first lockdown in England (April-July 2020); the other reported an uncertain decline in smoking prevalence in April 2020. Two prospective studies compared self-reported changes in consumption and attempts to quit at two time points, 12 months apart, during the pandemic; neither observed any change over time. Two cross-sectional studies and two qualitative studies described self-reported changes in smoking behaviour during the pandemic. The majority of other search results reported on the association between smoking status and risk of Covid-19 infection and outcomes; or included smoking status as a covariate in analyses of associations between other factors and the pandemic.
Added value of this study This study uses a nationally representative survey of adults in the general population in England, conducted monthly over a 5-year period, to estimate sustained impacts of the Covid-19 pandemic on smoking patterns. Unlike previous studies, which have focused on changes that occurred early in the pandemic, this study includes data up to August 2022 (two and a half years after the pandemic started) which allows us to understand whether any initial changes in smoking and quitting behaviour have been sustained over time. By collecting data monthly, this study is the first of its kind to have a large enough number of data points to undertake this kind of analysis (most representative surveys collect data annually). The findings are of direct relevance to the UK government’s aim to reduce smoking prevalence in England to less than 5% by 2030 and should inform a new tobacco control plan in England.
Implications of all the available evidence Before the Covid-19 pandemic, smoking prevalence had been falling among adults in England at a near linear rate for more than 20 years. This historic steady decline has almost completely stopped since the start of the pandemic. This may have been caused by a potential rise in uptake of smoking among young adults. These changes demand urgent, bold policy action, including measures to deter youth uptake of smoking and to support smokers to quit.
Competing Interest Statement
JB and EB have received unrestricted research funding from Pfizer, and JB only from J&J, who manufacture smoking cessation medications. LS has received honoraria for talks, an unrestricted research grant and travel expenses to attend meetings and workshops from Pfizer, and has acted as paid reviewer for grant awarding bodies and as a paid consultant for health care companies. All authors declare no financial links with tobacco companies, e-cigarette manufacturers, or their representatives.
Clinical Protocols
Funding Statement
Cancer Research UK funded the data collection and SJs salary (PRCRPG-Nov21\100002).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the STS was granted originally by the UCL Ethics Committee (ID 0498/001). The data are not collected by UCL and are anonymised when received by UCL.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data and code are available from the corresponding author on reasonable request.
